eViralHepatitis Review

eViralHepatitis Review


Latest Episodes

Avoiding “MELD Purgatory”
April 19, 2019

Volume 6, Issue 8 In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical practice.

Clinical Perspectives on Barriers To HBV Care
April 10, 2019

Volume 6, Issue 6 In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss how their analysis of the newer publi...

Clinical Insight: Engaging PWID in HCV Care
December 28, 2018

Volume 6, Issue 4. People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and imp...

In the Clinic: Identifying & Managing HCV Complications
October 26, 2018

Volume 6, Issue 2. In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD,

New Options for Patients with “Hard-To-Treat” Hepatitis C Infection
January 25, 2018

Volume 5, Issue 12. In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here.

Volume 5, Issue 10
November 30, 2017

Using Real World Data to Individualize HCV Management

Using Real World Data to Individualize HCV Management
November 30, 2017

Volume 5, Issue 10. In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter c...

Volume 5, Issue 8
September 28, 2017

Using Real World Data to Individualize HCV Management

Using Real World Data to Individualize HCV Management
September 28, 2017

Volume 5, Issue 8. In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks,

Volume 5, Issue 6
August 11, 2017

Clinical Insights: HCV and Substance Use Disorder